Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06092892 · ClinicalTrials.gov registry record · Phase 2
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
A Phase 2 study of Breast Cancer and Female Breast Cancer, sponsored by Alice Chung.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT06092892 is a Phase 2 study of Breast Cancer and Female Breast Cancer that is actively recruiting participants, run by Alice Chung. The registered enrollment target is 45 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06092892, a Phase 2 study of Breast Cancer and Female Breast Cancer, is actively recruiting participants, sponsored by Alice Chung.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Conditions Studied
Interventions
- PROCEDURE Breast Surgery (BCS or mastectomy) with TAD/SNB
- RADIATION Adjuvant Radiation Therapy
Study Locations (3)
California
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- CS Cancer at Huntington Cancer Center - Pasadena
- CS Cancer at Valley Oncology Medical Group - Tarzana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-04-07 |
| Est. Completion | 2031-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06092892
The ClinicalTrials.gov registry entry for NCT06092892 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Alice Chung, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Breast Surgery (BCS or mastectomy) with TAD/SNB is the first listed.
NCT06092892 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06092892 about?
NCT06092892 is a clinical study titled "IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases". The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective,...
What is the current status of trial NCT06092892?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-04-07. Estimated completion is 2031-04.
What conditions does trial NCT06092892 study?
This clinical trial studies the following conditions: Breast Cancer, Female Breast Cancer, Mastectomy; Lymphedema, Tumor, Breast, Axillary Nodal Disease.
What interventions are being tested in trial NCT06092892?
The interventions under investigation include: Breast Surgery (BCS or mastectomy) with TAD/SNB (PROCEDURE), Adjuvant Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06092892?
This trial is sponsored by Alice Chung, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06092892 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.